CoChat

PAK4 inhibition improves PD-1 blockade immunotherapy

Open access
Abril-Rodriguez, Gabriel, Torrejon, Davis Y., Liu, Wei, Zaretsky, Jesse M., Nowicki, Theodore S., Tsoi, Jennifer, Puig-Saus, Cristina, Baselga-Carretero, Ignacio, Medina, Egmidio, Quist, Michael J., Garcia, Alejandro J., Senapedis, William, Baloglu, Erkan, Kalbasi, Anusha, Cheung-Lau, Gardenia, Berent-Maoz, Beata, Comin-Anduix, Begoña, Hu-Lieskovan, Siwen, Wang, Cun-Yu, Grasso, Catherine S., Ribas, Antoni · 2019 · Nature Cancer
Cited by 157

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Lack of tumor infiltration by immune cells is the main mechanism of primary resistance to programmed cell death protein 1 (PD-1) blockade therapies for cancer. It has been postulated that cancer cell-intrinsic mechanisms may actively exclude T cells from tumors, suggesting that the finding of actionable molecules that could be inhibited to increase T cell infiltration may synergize with checkpoint inhibitor immunotherapy. Here, we show that p21-activated kinase 4 (PAK4) is enriched in non-responding tumor biopsies with low T cell and dendritic cell infiltration. In mouse models, genetic deletion of PAK4 increased T cell infiltration and reversed resistance to PD-1 blockade in a CD8 T cell-dependent manner. Furthermore, combination of anti-PD-1 with the PAK4 inhibitor KPT-9274 improved anti-tumor response compared with anti-PD-1 alone. Therefore, high PAK4 expression is correlated with low T cell and dendritic cell infiltration and a lack of response to PD-1 blockade, which could be reversed with PAK4 inhibition. Ribas and colleagues report that inhibition of PAK4 improves response to anti-PD-1 immunotherapy by reducing Wnt pathway activation and increasing tumor infiltration by T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-019-0003-0

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 157

Metadata

Authors
Abril-Rodriguez, G., Torrejon, D. Y., Liu, W., Zaretsky, J. M., Nowicki, T. S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M. J., Garcia, A. J., Senapedis, W., Baloglu, E., Kalbasi, A., Cheung-Lau, G., Berent-Maoz, B., Comin-Anduix, B., Hu-Lieskovan, S., Wang, C.-Y., Grasso, C. S., & Ribas, A.
Venue
Nature Cancer
Published
2019-12-09
Volume
1
Issue
1
Pages
46-58
ISSN
2662-1347 (ISSN-L)
OpenAlex
W2993691073
Cited by
157
References
18
FWCI
6.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PAK4 inhibition improves PD-1 blockade immunotherapy. https://app.cochat.ai/papers/10.1038/s43018-019-0003-0
The paper
Abril-Rodriguez, G., Torrejon, D. Y., Liu, W., Zaretsky, J. M., Nowicki, T. S., Tsoi, J., Puig-Saus, C., Baselga-Carretero, I., Medina, E., Quist, M. J., Garcia, A. J., Senapedis, W., Baloglu, E., Kalbasi, A., Cheung-Lau, G., Berent-Maoz, B., Comin-Anduix, B., Hu-Lieskovan, S., Wang, C.-Y., . . . Ribas, A. (2019). PAK4 inhibition improves PD-1 blockade immunotherapy. Nature Cancer. https://doi.org/10.1038/s43018-019-0003-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.